25030-31-3

Basic information

• Product Name: Adenosine, 5'-sulfaMate
• Synonyms: Adenosine, 5'-sulfaMate;5’Sulfamoyladenosine
• CAS NO: 25030-31-3
• Molecular Formula: C₁₀H₁₄N₆O₆S
• Molecular Weight: 346.31976
• Mol File: 25030-31-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 170 °C
• Boiling Point: 762.4±70.0 °C(Predicted)
• Appearance: /
• Density: 2.24±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 9.15±0.70(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: Adenosine, 5'-sulfaMate(CAS DataBase Reference)
• NIST Chemistry Reference: Adenosine, 5'-sulfaMate(25030-31-3)
• EPA Substance Registry System: Adenosine, 5'-sulfaMate(25030-31-3)

Safety Data

• Hazardous Substances Data: 25030-31-3(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 25030-31-3 differently. You can refer to the following data:
1. 5’Sulfamoyladenosine is used in studies relating to novel parasite inhibitors. In addition, it is used in the design and synthesis of β-ketosulfonamide adenylation inhibitors, as antitubercular antib iotics.
2. 5’-Sulfamoyladenosine is used in studies relating to novel parasite inhibitors. In addition, it is used in the design and synthesis of β-ketosulfonamide adenylation inhibitors, as antitubercular antibiotics.

Upstream product

• 69504-15-0 2',3'-O,O-bis(t-butyldimethylsilyl)adenosine 
• 64911-28-0 O^2'_,O3'_,O5'-tris-(tert-butyl-dimethyl-silanyl)-adenosine 
• 146-77-0 2-Chloroadenosine 
• 1356085-30-7 6-N-benzyloxycarbonyl-2',3'-O-benzylidene-5'-O-[N-(N-Cbz)-L-homoserinyl(OBn)sulfamoyl]adenosine 
• 1356085-27-2 6-N-benzyloxycarbonyl-2',3'-O-benzylidene-5'-O-[N-(N-Cbz-L-ornithinyl(δ-Cbz))-sulfamoyl]adenosine 
• 1356085-21-6 6-N-benzyloxycarbonyl-2',3'-O-benzylidene-5'-O-[N-(N-Cbz-L-lysinyl(ε-Cbz))sulfamoyl]adenosine 
• 64-17-5 ethanol 
• 1356085-18-1 6-N-benzyloxycarbonyl-2',3'-O-benzylidene-5'-O-[N-(N-Cbz-L-valinyl)sulfamoyl]adenosine 
• 58-61-7 adenosine 
• 362-75-4 2',3'-isopropylidene adenosine 
• 112921-00-3 ((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl sulfamate 
• 863238-53-3 2',3'-O-bis(tert-butyldimethylsilyl)-5'-O-(sulfamoyl)adenosine 

Relevant articles and documents

The synthesis of adenine 5'-O-sulfamoyl nucleosides related to nucleocidin.

-

Investigation, optimization and synthesis of sulfamoyloxy-linked aminoacyl-AMP analogues

Aminoacyl-tRNA synthetases (aaRSs) constitute a family of enzymes that transfer amino acids to their corresponding tRNA molecules to form aminoacyl-tRNAs and have been validated as potential drug targets. Sulfamoyloxy-linked aminoacyl-AMP analogues are potent inhibitors of aaRSs. In this article, we report the synthesis of several new sulfamoyl analogues of aa-AMP that up to now have been difficult or even impossible to prepare with current synthetic strategies. The developed synthetic strategy relies on performing the synthesis under neutral conditions followed by global deprotection using catalytic hydrogenation affording the desired 5′-O-(N-aminoacyl)sulfamoyladenosine compounds.

ANTI-MICROBIAL AGENTS AND USES THEREOF

Many pathogens, including Mycobacterium tuberculosis and Yersinia pestis, rely on an iron acquisition system based on siderophores, secreted iron-chelating compounds with extremely high Fe(III) affinity. The compounds of the invention are inhibitors of domain salicylation enzymes, which catalyze the salicylation of an aroyl carrier protein (ArCP) domain to form a salicyl-ArCP domain thioester intermediate via a two-step reaction. The compounds include the intermediate mimic 5 '-O- [N- (salicyl)sulfamoyl] -adenosine (salicyl-AMS) and analogs thereof. These compounds are inhibitors of the salicylate activity of MbtA, YbtE, PchD, and other domain salicylation enzymes involved in the biosynthesis of siderophores. Therefore, these compounds may be used in the treatment of infection caused by microorganisms which rely on siderphore-based iron acquisition systems. Pharmaceutical composition and methods of using these compounds to treat or prevent infection are also provided as well as methods of preparing the inventive compounds.